{"id":4875,"date":"2022-09-13T06:00:18","date_gmt":"2022-09-13T11:00:18","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=4875"},"modified":"2025-07-25T11:23:37","modified_gmt":"2025-07-25T16:23:37","slug":"nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ar\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/","title":{"rendered":"\u062a\u0639\u0644\u0646 \u0634\u0631\u0643\u0629 Nanscope Therapeutics \u0639\u0646 \u0627\u0633\u062a\u0643\u0645\u0627\u0644 \u0627\u0644\u062a\u0633\u062c\u064a\u0644 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0640 STARLIGHT \u0644\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u064a\u0646\u064a \u0627\u0644\u0628\u0635\u0631\u064a MCO-010 \u0644\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a"},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u0645\u0646 \u0627\u0644\u0645\u062a\u0648\u0642\u0639 \u0635\u062f\u0648\u0631 \u0628\u064a\u0627\u0646\u0627\u062a \u0633\u062a\u0629 \u0623\u0634\u0647\u0631 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u062a\u062c\u0631\u0628\u0629 STARLIGHT \u0641\u064a \u0627\u0644\u0646\u0635\u0641 \u0627\u0644\u0623\u0648\u0644 \u0645\u0646 \u0639\u0627\u0645 2023<\/i><\/strong><\/p>

\u062f\u0627\u0644\u0627\u0633<\/span><\/span>,\u00a013 \u0633\u0628\u062a\u0645\u0628\u0631 2022<\/span><\/span>\u00a0 \u2014 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u0644\u0644\u0639\u0644\u0627\u062c\u0627\u062a<\/a>\u0623\u0639\u0644\u0646\u062a \u0627\u0644\u064a\u0648\u0645 \u0634\u0631\u0643\u0629 \u0627\u0644\u062a\u0643\u0646\u0648\u0644\u0648\u062c\u064a\u0627 \u0627\u0644\u062d\u064a\u0648\u064a\u0629 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0648\u0627\u0644\u062a\u064a \u062a\u0639\u0645\u0644 \u0639\u0644\u0649 \u062a\u0637\u0648\u064a\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u062c\u064a\u0646\u064a\u0629 \u0644\u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633 \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0639\u0646 \u0627\u0644\u062a\u0633\u062c\u064a\u0644 \u0627\u0644\u0643\u0627\u0645\u0644 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u062a\u062c\u0631\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0640 MCO-010\u060c \u0648\u0647\u0648 \u0639\u0644\u0627\u062c \u0636\u0648\u0626\u064a \u0623\u062d\u0627\u062f\u064a \u0645\u062a\u0639\u062f\u062f \u0627\u0644\u062e\u0635\u0627\u0626\u0635 Opsin (MCO) \u0642\u0627\u0628\u0644 \u0644\u0644\u062a\u0646\u0634\u064a\u0637 \u0641\u064a \u0627\u0644\u0636\u0648\u0621 \u0627\u0644\u0645\u062d\u064a\u0637 \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0631\u0624\u064a\u0629 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0645\u0643\u0641\u0648\u0641\u064a\u0646. \u0644\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a. \u0645\u0646 \u0627\u0644\u0645\u062a\u0648\u0642\u0639 \u0635\u062f\u0648\u0631 \u0628\u064a\u0627\u0646\u0627\u062a \u0633\u062a\u0629 \u0623\u0634\u0647\u0631 \u0645\u0646 \u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0644\u0640 STARLIGHT \u0641\u064a \u0627\u0644\u0646\u0635\u0641 \u0627\u0644\u0623\u0648\u0644 \u0645\u0646 \u0639\u0627\u0645 2023.<\/p>

\u201c"\u0646\u062d\u0646 \u0645\u062a\u062d\u0645\u0633\u0648\u0646 \u0644\u0644\u0625\u0645\u0643\u0627\u0646\u0627\u062a \u0627\u0644\u0639\u0644\u0627\u062c\u064a\u0629 \u0644\u0640 MCO-010\u060c \u0627\u0644\u0645\u062f\u0639\u0648\u0645\u0629 \u0628\u0628\u064a\u0627\u0646\u0627\u062a \u0642\u0648\u064a\u0629 \u0645\u0646 \u0627\u0644\u062f\u0631\u0627\u0633\u0627\u062a \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0648\u0645\u0627 \u0642\u0628\u0644 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0627\u0644\u0633\u0627\u0628\u0642\u0629"\u060c \u0642\u0627\u0644\u00a0\u0633\u0648\u0644\u0627\u062c\u0646\u0627 \u0628\u0647\u0627\u062a\u0627\u0634\u0627\u0631\u064a\u0627<\/span>, \u060c \u0627\u0644\u0631\u0626\u064a\u0633 \u0627\u0644\u062a\u0646\u0641\u064a\u0630\u064a \u0644\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628. "\u0625\u0646 \u0625\u0643\u0645\u0627\u0644 \u0627\u0644\u062a\u0633\u062c\u064a\u0644 \u0627\u0644\u0633\u0631\u064a\u0639 \u0644\u0645\u062f\u0629 \u0634\u0647\u0631\u064a\u0646 \u0644\u0647\u0630\u0647 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u0633\u062a\u0642\u064a\u0651\u0645 \u0633\u0644\u0627\u0645\u0629 \u0648\u0641\u0639\u0627\u0644\u064a\u0629 \u062d\u0642\u0646\u0629 \u0648\u0627\u062d\u062f\u0629 \u062f\u0627\u062e\u0644 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a \u0645\u0646 MCO-010\u060c \u064a\u0645\u062b\u0644 \u062e\u0637\u0648\u0629 \u0631\u0626\u064a\u0633\u064a\u0629 \u0623\u062e\u0631\u0649 \u0625\u0644\u0649 \u0627\u0644\u0623\u0645\u0627\u0645 \u0641\u064a \u062a\u0637\u0648\u064a\u0631 \u0647\u0630\u0627 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u062f\u064a\u062f \u0630\u064a \u0627\u0644\u062a\u0637\u0628\u064a\u0642 \u0627\u0644\u0639\u0644\u0627\u062c\u064a \u0627\u0644\u0648\u0627\u0633\u0639."\u201c<\/p>

\u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u062a\u062c\u0631\u0628\u0629 STARLIGHT \u0630\u0627\u062a \u0627\u0644\u062a\u0633\u0645\u064a\u0629 \u0627\u0644\u0645\u0641\u062a\u0648\u062d\u0629 (NCT05417126<\/a>\u0623\u064f\u062f\u0631\u062c \u0633\u062a\u0629 \u0645\u0631\u0636\u0649 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0628\u0635\u0631 \u0645\u062a\u0642\u062f\u0645 \u0646\u062a\u064a\u062c\u0629 \u062a\u0634\u062e\u064a\u0635 \u0633\u0631\u064a\u0631\u064a \u0623\u0648 \u062c\u064a\u0646\u064a \u0644\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a. \u0641\u064a \u0647\u0630\u0647 \u0627\u0644\u062f\u0631\u0627\u0633\u0629\u060c \u062a\u0644\u0642\u0649 \u062c\u0645\u064a\u0639 \u0627\u0644\u0645\u0631\u0636\u0649 \u0646\u0641\u0633 \u0627\u0644\u062c\u0631\u0639\u0629 \u0627\u0644\u0645\u0641\u0631\u062f\u0629 \u062f\u0627\u062e\u0644 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a \u0645\u0646 MCO-010\u060c \u0648\u0647\u064a 1.2 \u00d7 10\u00b9\u00b9 \u062c\u0632\u064a\u0621\/\u0639\u064a\u0646\u060c \u0643\u0645\u0627 \u0627\u0633\u062a\u064f\u062e\u062f\u0645\u062a \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0644\u0634\u0631\u0643\u0629.\u00a02\u0628<\/span>\u00a0\u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP).<\/p>

\u201c"\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a \u0647\u0648 \u062d\u0627\u0644\u0629 \u062a\u0633\u0628\u0628 \u0627\u0644\u0639\u0645\u0649 \u0648\u062a\u0635\u064a\u0628 \u0627\u0644\u0628\u0627\u0644\u063a\u064a\u0646 \u0648\u0627\u0644\u0623\u0637\u0641\u0627\u0644 \u0639\u0644\u0649 \u062d\u062f \u0633\u0648\u0627\u0621. \u0648\u0647\u0648 \u0623\u0643\u062b\u0631 \u0623\u0646\u0648\u0627\u0639 \u0636\u0645\u0648\u0631 \u0627\u0644\u0628\u0642\u0639\u0629 \u0634\u064a\u0648\u0639\u064b\u0627\u060c \u0648\u0644\u0627 \u064a\u0648\u062c\u062f \u0644\u0647 \u0639\u0644\u0627\u062c \u0645\u0639\u062a\u0645\u062f"\u060c \u0647\u0630\u0627 \u0645\u0627 \u0642\u0627\u0644\u0647 \u0627\u0644\u062f\u0643\u062a\u0648\u0631 \u0628\u0627\u064a\u0631\u0648\u0646 \u0644\u0627\u0645\u060c \u0631\u0626\u064a\u0633 \u0642\u0633\u0645 \u0637\u0628 \u0627\u0644\u0639\u064a\u0648\u0646 \u0648\u0623\u0633\u062a\u0627\u0630 \u0643\u0631\u0633\u064a \u0631\u0648\u0628\u0631\u062a \u0632\u062f \u0648\u0646\u0627\u0646\u0633\u064a \u062c\u064a\u0647 \u063a\u0631\u064a\u0646 \u0641\u064a \u062c\u0627\u0645\u0639\u0629\u00a0\u062c\u0627\u0645\u0639\u0629 \u0645\u064a\u0627\u0645\u064a<\/span>\u00a0\u0648\u0627\u0644\u0628\u0627\u062d\u062b \u0627\u0644\u0631\u0626\u064a\u0633\u064a \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u062a\u062c\u0631\u0628\u0629 STARLIGHT. "\u064a\u062a\u0645\u062a\u0639 MCO-010 \u0628\u0625\u0645\u0643\u0627\u0646\u064a\u0629 \u062a\u062d\u0633\u064a\u0646 \u0648\u0638\u0627\u0626\u0641 \u0627\u0644\u0625\u0628\u0635\u0627\u0631 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a \u0648\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a\u060c \u0648\u0646\u062a\u0637\u0644\u0639 \u0625\u0644\u0649 \u0627\u0644\u0627\u0637\u0644\u0627\u0639 \u0639\u0644\u0649 \u0628\u064a\u0627\u0646\u0627\u062a \u0647\u0630\u0647 \u0627\u0644\u062f\u0631\u0627\u0633\u0629."\u201c<\/p>

\u062a\u0633\u062a\u062e\u062f\u0645 \u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0628\u0635\u0631\u064a \u0627\u0644\u0648\u0631\u0627\u062b\u064a \u0645\u0646 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 \u062e\u0627\u0635\u0629 \u0628\u0647\u0627\u00a0\u0623\u06412<\/i>\u00a0\u0646\u0627\u0642\u0644\u064c \u0644\u0625\u064a\u0635\u0627\u0644 \u062c\u064a\u0646\u0627\u062a MCO \u0625\u0644\u0649 \u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0644\u062a\u0645\u0643\u064a\u0646 \u0627\u0644\u0631\u0624\u064a\u0629 \u0641\u064a \u0628\u064a\u0626\u0627\u062a \u0644\u0648\u0646\u064a\u0629 \u0645\u062e\u062a\u0644\u0641\u0629. \u064a\u064f\u0639\u0637\u0649 \u0627\u0644\u0639\u0644\u0627\u062c \u0643\u062d\u0642\u0646\u0629 \u0648\u0627\u062d\u062f\u0629 \u062f\u0627\u062e\u0644 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a \u0644\u0644\u0639\u064a\u0646\u060c \u0648\u064a\u0645\u0643\u0646 \u0625\u0639\u0637\u0627\u0624\u0647 \u0641\u064a \u0627\u0644\u0639\u064a\u0627\u062f\u0629 \u062f\u0648\u0646 \u0627\u0644\u062d\u0627\u062c\u0629 \u0625\u0644\u0649 \u0623\u064a \u0623\u062c\u0647\u0632\u0629 \u0623\u0648 \u062a\u062f\u062e\u0644\u0627\u062a \u0623\u062e\u0631\u0649. \u062d\u0635\u0644 MCO-010 \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641 \u062f\u0648\u0627\u0621 \u064a\u062a\u064a\u0645 \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a \u0648\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a\u060c \u0648\u064a\u062c\u0631\u064a \u062a\u0642\u064a\u064a\u0645\u0647 \u062d\u0627\u0644\u064a\u064b\u0627 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0644\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628.\u00a02\u0628<\/span>\u00a0\u062a\u062c\u0631\u0628\u0629 RESTORE \u0639\u0644\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 RP\u060c \u0648\u0645\u0646 \u0627\u0644\u0645\u062a\u0648\u0642\u0639 \u0623\u064a\u0636\u064b\u0627 \u0638\u0647\u0648\u0631 \u0646\u062a\u0627\u0626\u062c \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0641\u064a \u0627\u0644\u0646\u0635\u0641 \u0627\u0644\u0623\u0648\u0644 \u0645\u0646 \u0639\u0627\u0645 2023.<\/p>

\u062d\u0648\u0644 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u064a\u0643\u0633 \u0625\u0646\u0643.<\/b><\/div>

\u062a\u0639\u0645\u0644 \u0634\u0631\u0643\u0629 Nanoscope Therapeutics \u0639\u0644\u0649 \u062a\u0637\u0648\u064a\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u0628\u0635\u0631\u064a\u0629 \u0648\u0631\u0627\u062b\u064a\u0629 \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631\u060c \u0644\u0627 \u062a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0627\u0644\u062c\u064a\u0646\u0627\u062a\u060c \u0644\u0645\u0644\u0627\u064a\u064a\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u0641\u0642\u062f\u0648\u0627 \u0628\u0635\u0631\u0647\u0645 \u0628\u0633\u0628\u0628 \u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633\u064a\u0629 \u0641\u064a \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u0644\u0627 \u064a\u0648\u062c\u062f \u0644\u0647\u0627 \u0639\u0644\u0627\u062c \u062d\u062a\u0649 \u0627\u0644\u0622\u0646. \u0648\u064a\u062e\u0636\u0639 \u0645\u0646\u062a\u062c \u0627\u0644\u0634\u0631\u0643\u0629 \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u060c MCO-010\u060c \u062d\u0627\u0644\u064a\u064b\u0627 \u0644\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062a\u062c\u0631\u064a\u0628\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649.\u00a02\u0628<\/span>\u00a0\u062a\u062c\u0627\u0631\u0628 \u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0645\u0631\u0627\u0643\u0632\u060c \u0639\u0634\u0648\u0627\u0626\u064a\u0629\u060c \u0645\u0632\u062f\u0648\u062c\u0629 \u0627\u0644\u0642\u0646\u0627\u0639\u060c \u062e\u0627\u0636\u0639\u0629 \u0644\u0644\u062a\u062d\u0643\u0645 \u0627\u0644\u0632\u0627\u0626\u0641 \u0641\u064a \u0627\u0644\u0648\u0644\u0627\u064a\u0627\u062a \u0627\u0644\u0645\u062a\u062d\u062f\u0629 \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (NCT04945772<\/a>) \u0645\u0639 \u062a\u0648\u0642\u0639 \u0627\u0644\u0628\u064a\u0627\u0646\u0627\u062a \u0627\u0644\u0639\u0644\u064a\u0627 \u0641\u064a \u0627\u0644\u0646\u0635\u0641 \u0627\u0644\u0623\u0648\u0644 \u0645\u0646 \u0639\u0627\u0645 2023. \u0648\u0628\u062f\u0623\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u0623\u064a\u0636\u064b\u0627 \u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0639\u0644\u0627\u062c MCO-010 \u0641\u064a \u0645\u0631\u0636\u0649 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a (NCT05417126<\/a>). \u062d\u0635\u0644 MCO-010 \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u064a\u062a\u064a\u0645\u0629 \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0640 RP \u0648Stargardt. \u062a\u0634\u0645\u0644 \u0627\u0644\u0623\u0635\u0648\u0644 \u0642\u0628\u0644 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u064a\u0646\u064a MCO-020 \u0628\u0627\u0644\u0644\u064a\u0632\u0631 \u063a\u064a\u0631 \u0627\u0644\u0641\u064a\u0631\u0648\u0633\u064a \u0644\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a.<\/p>

\u0627\u0644\u0627\u062a\u0635\u0627\u0644 \u0628\u0627\u0644\u0645\u0633\u062a\u062b\u0645\u0631:<\/b>
\u0634\u0631\u0643\u0627\u0621 \u0623\u0631\u063a\u0648\u062a
212-600-1902
Nanoscope@argotpartners.com<\/a><\/p>

\u0627\u0644\u0645\u0635\u062f\u0631 \u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Six-month data from Phase 2 STARLIGHT trial expected in H1 2023 DALLAS,\u00a0Sept. 13, 2022\u00a0 \u2014 Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full enrollment of its Phase 2 clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, […]<\/p>\n","protected":false},"author":6,"featured_media":4876,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-4875","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ar\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ar\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-13T11:00:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-25T16:23:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"\u062f\u0642\u064a\u0642\u062a\u0627\u0646\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease\",\"datePublished\":\"2022-09-13T11:00:18+00:00\",\"dateModified\":\"2025-07-25T16:23:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/\"},\"wordCount\":464,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ar\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/\",\"name\":\"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg\",\"datePublished\":\"2022-09-13T11:00:18+00:00\",\"dateModified\":\"2025-07-25T16:23:37+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2022\\\/09\\\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2022\\\/09\\\/13\\\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0639\u0646 \u0627\u0643\u062a\u0645\u0627\u0644 \u062a\u0633\u062c\u064a\u0644 \u0627\u0644\u0645\u0631\u0636\u0649 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 STARLIGHT \u0644\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u064a\u0646\u064a \u0627\u0644\u0628\u0635\u0631\u064a \u0627\u0644\u0648\u0631\u0627\u062b\u064a MCO-010 \u0644\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a - \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ar\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/","og_locale":"ar_AR","og_type":"article","og_title":"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ar\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2022-09-13T11:00:18+00:00","article_modified_time":"2025-07-25T16:23:37+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"Nanoscope Therapeutics","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"\u062f\u0642\u064a\u0642\u062a\u0627\u0646"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease","datePublished":"2022-09-13T11:00:18+00:00","dateModified":"2025-07-25T16:23:37+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/"},"wordCount":464,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ar"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/","url":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/","name":"\u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0639\u0646 \u0627\u0643\u062a\u0645\u0627\u0644 \u062a\u0633\u062c\u064a\u0644 \u0627\u0644\u0645\u0631\u0636\u0649 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 STARLIGHT \u0644\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062c\u064a\u0646\u064a \u0627\u0644\u0628\u0635\u0631\u064a \u0627\u0644\u0648\u0631\u0627\u062b\u064a MCO-010 \u0644\u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a - \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg","datePublished":"2022-09-13T11:00:18+00:00","dateModified":"2025-07-25T16:23:37+00:00","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2022\/09\/NSCOPE_LI_Starlight_full_enrollment_V1.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2022\/09\/13\/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628","description":"\u0625\u0639\u0627\u062f\u0629 \u0646\u0648\u0631 \u0627\u0644\u0623\u0645\u0644","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/4875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/comments?post=4875"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/4875\/revisions"}],"predecessor-version":[{"id":9244,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/4875\/revisions\/9244"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media\/4876"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media?parent=4875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/categories?post=4875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/tags?post=4875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}